Eintrag weiter verarbeiten
Smoothened Antagonists Reverse Taxane Resistance in Ovarian Cancer
Gespeichert in:
| Zeitschriftentitel: | Molecular Cancer Therapeutics |
|---|---|
| Personen und Körperschaften: | , , , , , , , |
| In: | Molecular Cancer Therapeutics, 11, 2012, 7, S. 1587-1597 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Association for Cancer Research (AACR)
|
| Schlagwörter: |
| author_facet |
Steg, Adam D. Katre, Ashwini A. Bevis, Kerri S. Ziebarth, Angela Dobbin, Zachary C. Shah, Monjri M. Alvarez, Ronald D. Landen, Charles N. Steg, Adam D. Katre, Ashwini A. Bevis, Kerri S. Ziebarth, Angela Dobbin, Zachary C. Shah, Monjri M. Alvarez, Ronald D. Landen, Charles N. |
|---|---|
| author |
Steg, Adam D. Katre, Ashwini A. Bevis, Kerri S. Ziebarth, Angela Dobbin, Zachary C. Shah, Monjri M. Alvarez, Ronald D. Landen, Charles N. |
| spellingShingle |
Steg, Adam D. Katre, Ashwini A. Bevis, Kerri S. Ziebarth, Angela Dobbin, Zachary C. Shah, Monjri M. Alvarez, Ronald D. Landen, Charles N. Molecular Cancer Therapeutics Smoothened Antagonists Reverse Taxane Resistance in Ovarian Cancer Cancer Research Oncology |
| author_sort |
steg, adam d. |
| spelling |
Steg, Adam D. Katre, Ashwini A. Bevis, Kerri S. Ziebarth, Angela Dobbin, Zachary C. Shah, Monjri M. Alvarez, Ronald D. Landen, Charles N. 1535-7163 1538-8514 American Association for Cancer Research (AACR) Cancer Research Oncology http://dx.doi.org/10.1158/1535-7163.mct-11-1058 <jats:title>Abstract</jats:title> <jats:p>The hedgehog pathway has been implicated in the formation and maintenance of a variety of malignancies, including ovarian cancer; however, it is unknown whether hedgehog signaling is involved in ovarian cancer chemoresistance. The goal of this study was to determine the effects of antagonizing the hedgehog receptor, Smoothened (Smo), on chemotherapy response in ovarian cancer. Expression of hedgehog pathway members was assessed in three pairs of parental and chemotherapy-resistant ovarian cancer cell lines (A2780ip2/A2780cp20, SKOV3ip1/SKOV3TRip2, HeyA8/HeyA8MDR) using quantitative PCR and Western blot analysis. Cell lines were exposed to increasing concentrations of two different Smo antagonists (cyclopamine, LDE225) alone and in combination with carboplatin or paclitaxel. Selective knockdown of Smo, Gli1, or Gli2 was achieved using siRNA constructs. Cell viability was assessed by MTT assay. A2780cp20 and SKOV3TRip2 orthotopic xenografts were treated with vehicle, LDE225, paclitaxel, or combination therapy. Chemoresistant cell lines showed higher expression (&gt;2-fold, P &lt; 0.05) of hedgehog signaling components compared with their respective parental lines. Smo antagonists sensitized chemotherapy-resistant cell lines to paclitaxel, but not to carboplatin. LDE225 treatment also increased sensitivity of ALDH-positive cells to paclitaxel. A2780cp20 and SKOV3TRip2 xenografts treated with combined LDE225 and paclitaxel had significantly less tumor burden than those treated with vehicle or either agent alone. Increased taxane sensitivity seems to be mediated by a decrease in P-glycoprotein (MDR1) expression. Selective knockdown of Smo, Gli1, or Gli2 all increased taxane sensitivity. Smo antagonists reverse taxane resistance in chemoresistant ovarian cancer models, suggesting combined anti-hedgehog and chemotherapies could provide a useful therapeutic strategy for ovarian cancer. Mol Cancer Ther; 11(7); 1587–97. ©2012 AACR.</jats:p> Smoothened Antagonists Reverse Taxane Resistance in Ovarian Cancer Molecular Cancer Therapeutics |
| doi_str_mv |
10.1158/1535-7163.mct-11-1058 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8xNTM1LTcxNjMubWN0LTExLTEwNTg |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8xNTM1LTcxNjMubWN0LTExLTEwNTg |
| institution |
DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Rs1 DE-Pl11 DE-105 DE-14 DE-Ch1 DE-L229 |
| imprint |
American Association for Cancer Research (AACR), 2012 |
| imprint_str_mv |
American Association for Cancer Research (AACR), 2012 |
| issn |
1538-8514 1535-7163 |
| issn_str_mv |
1538-8514 1535-7163 |
| language |
English |
| mega_collection |
American Association for Cancer Research (AACR) (CrossRef) |
| match_str |
steg2012smoothenedantagonistsreversetaxaneresistanceinovariancancer |
| publishDateSort |
2012 |
| publisher |
American Association for Cancer Research (AACR) |
| recordtype |
ai |
| record_format |
ai |
| series |
Molecular Cancer Therapeutics |
| source_id |
49 |
| title |
Smoothened Antagonists Reverse Taxane Resistance in Ovarian Cancer |
| title_unstemmed |
Smoothened Antagonists Reverse Taxane Resistance in Ovarian Cancer |
| title_full |
Smoothened Antagonists Reverse Taxane Resistance in Ovarian Cancer |
| title_fullStr |
Smoothened Antagonists Reverse Taxane Resistance in Ovarian Cancer |
| title_full_unstemmed |
Smoothened Antagonists Reverse Taxane Resistance in Ovarian Cancer |
| title_short |
Smoothened Antagonists Reverse Taxane Resistance in Ovarian Cancer |
| title_sort |
smoothened antagonists reverse taxane resistance in ovarian cancer |
| topic |
Cancer Research Oncology |
| url |
http://dx.doi.org/10.1158/1535-7163.mct-11-1058 |
| publishDate |
2012 |
| physical |
1587-1597 |
| description |
<jats:title>Abstract</jats:title>
<jats:p>The hedgehog pathway has been implicated in the formation and maintenance of a variety of malignancies, including ovarian cancer; however, it is unknown whether hedgehog signaling is involved in ovarian cancer chemoresistance. The goal of this study was to determine the effects of antagonizing the hedgehog receptor, Smoothened (Smo), on chemotherapy response in ovarian cancer. Expression of hedgehog pathway members was assessed in three pairs of parental and chemotherapy-resistant ovarian cancer cell lines (A2780ip2/A2780cp20, SKOV3ip1/SKOV3TRip2, HeyA8/HeyA8MDR) using quantitative PCR and Western blot analysis. Cell lines were exposed to increasing concentrations of two different Smo antagonists (cyclopamine, LDE225) alone and in combination with carboplatin or paclitaxel. Selective knockdown of Smo, Gli1, or Gli2 was achieved using siRNA constructs. Cell viability was assessed by MTT assay. A2780cp20 and SKOV3TRip2 orthotopic xenografts were treated with vehicle, LDE225, paclitaxel, or combination therapy. Chemoresistant cell lines showed higher expression (&gt;2-fold, P &lt; 0.05) of hedgehog signaling components compared with their respective parental lines. Smo antagonists sensitized chemotherapy-resistant cell lines to paclitaxel, but not to carboplatin. LDE225 treatment also increased sensitivity of ALDH-positive cells to paclitaxel. A2780cp20 and SKOV3TRip2 xenografts treated with combined LDE225 and paclitaxel had significantly less tumor burden than those treated with vehicle or either agent alone. Increased taxane sensitivity seems to be mediated by a decrease in P-glycoprotein (MDR1) expression. Selective knockdown of Smo, Gli1, or Gli2 all increased taxane sensitivity. Smo antagonists reverse taxane resistance in chemoresistant ovarian cancer models, suggesting combined anti-hedgehog and chemotherapies could provide a useful therapeutic strategy for ovarian cancer. Mol Cancer Ther; 11(7); 1587–97. ©2012 AACR.</jats:p> |
| container_issue |
7 |
| container_start_page |
1587 |
| container_title |
Molecular Cancer Therapeutics |
| container_volume |
11 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792341996167233537 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T16:28:46.696Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Smoothened+Antagonists+Reverse+Taxane+Resistance+in+Ovarian+Cancer&rft.date=2012-07-01&genre=article&issn=1538-8514&volume=11&issue=7&spage=1587&epage=1597&pages=1587-1597&jtitle=Molecular+Cancer+Therapeutics&atitle=Smoothened+Antagonists+Reverse+Taxane+Resistance+in+Ovarian+Cancer&aulast=Landen&aufirst=Charles+N.&rft_id=info%3Adoi%2F10.1158%2F1535-7163.mct-11-1058&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792341996167233537 |
| author | Steg, Adam D., Katre, Ashwini A., Bevis, Kerri S., Ziebarth, Angela, Dobbin, Zachary C., Shah, Monjri M., Alvarez, Ronald D., Landen, Charles N. |
| author_facet | Steg, Adam D., Katre, Ashwini A., Bevis, Kerri S., Ziebarth, Angela, Dobbin, Zachary C., Shah, Monjri M., Alvarez, Ronald D., Landen, Charles N., Steg, Adam D., Katre, Ashwini A., Bevis, Kerri S., Ziebarth, Angela, Dobbin, Zachary C., Shah, Monjri M., Alvarez, Ronald D., Landen, Charles N. |
| author_sort | steg, adam d. |
| container_issue | 7 |
| container_start_page | 1587 |
| container_title | Molecular Cancer Therapeutics |
| container_volume | 11 |
| description | <jats:title>Abstract</jats:title> <jats:p>The hedgehog pathway has been implicated in the formation and maintenance of a variety of malignancies, including ovarian cancer; however, it is unknown whether hedgehog signaling is involved in ovarian cancer chemoresistance. The goal of this study was to determine the effects of antagonizing the hedgehog receptor, Smoothened (Smo), on chemotherapy response in ovarian cancer. Expression of hedgehog pathway members was assessed in three pairs of parental and chemotherapy-resistant ovarian cancer cell lines (A2780ip2/A2780cp20, SKOV3ip1/SKOV3TRip2, HeyA8/HeyA8MDR) using quantitative PCR and Western blot analysis. Cell lines were exposed to increasing concentrations of two different Smo antagonists (cyclopamine, LDE225) alone and in combination with carboplatin or paclitaxel. Selective knockdown of Smo, Gli1, or Gli2 was achieved using siRNA constructs. Cell viability was assessed by MTT assay. A2780cp20 and SKOV3TRip2 orthotopic xenografts were treated with vehicle, LDE225, paclitaxel, or combination therapy. Chemoresistant cell lines showed higher expression (&gt;2-fold, P &lt; 0.05) of hedgehog signaling components compared with their respective parental lines. Smo antagonists sensitized chemotherapy-resistant cell lines to paclitaxel, but not to carboplatin. LDE225 treatment also increased sensitivity of ALDH-positive cells to paclitaxel. A2780cp20 and SKOV3TRip2 xenografts treated with combined LDE225 and paclitaxel had significantly less tumor burden than those treated with vehicle or either agent alone. Increased taxane sensitivity seems to be mediated by a decrease in P-glycoprotein (MDR1) expression. Selective knockdown of Smo, Gli1, or Gli2 all increased taxane sensitivity. Smo antagonists reverse taxane resistance in chemoresistant ovarian cancer models, suggesting combined anti-hedgehog and chemotherapies could provide a useful therapeutic strategy for ovarian cancer. Mol Cancer Ther; 11(7); 1587–97. ©2012 AACR.</jats:p> |
| doi_str_mv | 10.1158/1535-7163.mct-11-1058 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8xNTM1LTcxNjMubWN0LTExLTEwNTg |
| imprint | American Association for Cancer Research (AACR), 2012 |
| imprint_str_mv | American Association for Cancer Research (AACR), 2012 |
| institution | DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Rs1, DE-Pl11, DE-105, DE-14, DE-Ch1, DE-L229 |
| issn | 1538-8514, 1535-7163 |
| issn_str_mv | 1538-8514, 1535-7163 |
| language | English |
| last_indexed | 2024-03-01T16:28:46.696Z |
| match_str | steg2012smoothenedantagonistsreversetaxaneresistanceinovariancancer |
| mega_collection | American Association for Cancer Research (AACR) (CrossRef) |
| physical | 1587-1597 |
| publishDate | 2012 |
| publishDateSort | 2012 |
| publisher | American Association for Cancer Research (AACR) |
| record_format | ai |
| recordtype | ai |
| series | Molecular Cancer Therapeutics |
| source_id | 49 |
| spelling | Steg, Adam D. Katre, Ashwini A. Bevis, Kerri S. Ziebarth, Angela Dobbin, Zachary C. Shah, Monjri M. Alvarez, Ronald D. Landen, Charles N. 1535-7163 1538-8514 American Association for Cancer Research (AACR) Cancer Research Oncology http://dx.doi.org/10.1158/1535-7163.mct-11-1058 <jats:title>Abstract</jats:title> <jats:p>The hedgehog pathway has been implicated in the formation and maintenance of a variety of malignancies, including ovarian cancer; however, it is unknown whether hedgehog signaling is involved in ovarian cancer chemoresistance. The goal of this study was to determine the effects of antagonizing the hedgehog receptor, Smoothened (Smo), on chemotherapy response in ovarian cancer. Expression of hedgehog pathway members was assessed in three pairs of parental and chemotherapy-resistant ovarian cancer cell lines (A2780ip2/A2780cp20, SKOV3ip1/SKOV3TRip2, HeyA8/HeyA8MDR) using quantitative PCR and Western blot analysis. Cell lines were exposed to increasing concentrations of two different Smo antagonists (cyclopamine, LDE225) alone and in combination with carboplatin or paclitaxel. Selective knockdown of Smo, Gli1, or Gli2 was achieved using siRNA constructs. Cell viability was assessed by MTT assay. A2780cp20 and SKOV3TRip2 orthotopic xenografts were treated with vehicle, LDE225, paclitaxel, or combination therapy. Chemoresistant cell lines showed higher expression (&gt;2-fold, P &lt; 0.05) of hedgehog signaling components compared with their respective parental lines. Smo antagonists sensitized chemotherapy-resistant cell lines to paclitaxel, but not to carboplatin. LDE225 treatment also increased sensitivity of ALDH-positive cells to paclitaxel. A2780cp20 and SKOV3TRip2 xenografts treated with combined LDE225 and paclitaxel had significantly less tumor burden than those treated with vehicle or either agent alone. Increased taxane sensitivity seems to be mediated by a decrease in P-glycoprotein (MDR1) expression. Selective knockdown of Smo, Gli1, or Gli2 all increased taxane sensitivity. Smo antagonists reverse taxane resistance in chemoresistant ovarian cancer models, suggesting combined anti-hedgehog and chemotherapies could provide a useful therapeutic strategy for ovarian cancer. Mol Cancer Ther; 11(7); 1587–97. ©2012 AACR.</jats:p> Smoothened Antagonists Reverse Taxane Resistance in Ovarian Cancer Molecular Cancer Therapeutics |
| spellingShingle | Steg, Adam D., Katre, Ashwini A., Bevis, Kerri S., Ziebarth, Angela, Dobbin, Zachary C., Shah, Monjri M., Alvarez, Ronald D., Landen, Charles N., Molecular Cancer Therapeutics, Smoothened Antagonists Reverse Taxane Resistance in Ovarian Cancer, Cancer Research, Oncology |
| title | Smoothened Antagonists Reverse Taxane Resistance in Ovarian Cancer |
| title_full | Smoothened Antagonists Reverse Taxane Resistance in Ovarian Cancer |
| title_fullStr | Smoothened Antagonists Reverse Taxane Resistance in Ovarian Cancer |
| title_full_unstemmed | Smoothened Antagonists Reverse Taxane Resistance in Ovarian Cancer |
| title_short | Smoothened Antagonists Reverse Taxane Resistance in Ovarian Cancer |
| title_sort | smoothened antagonists reverse taxane resistance in ovarian cancer |
| title_unstemmed | Smoothened Antagonists Reverse Taxane Resistance in Ovarian Cancer |
| topic | Cancer Research, Oncology |
| url | http://dx.doi.org/10.1158/1535-7163.mct-11-1058 |